These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35203481)

  • 1. Reducing the Pill Burden: Immunosuppressant Adherence and Safety after Conversion from a Twice-Daily (IR-Tac) to a Novel Once-Daily (LCP-Tac) Tacrolimus Formulation in 161 Liver Transplant Patients.
    Maurer MM; Ibach M; Plewe J; Winter A; Ritschl P; Globke B; Öllinger R; Lurje G; Schöning W; Pratschke J; Eurich D
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LCP-Tacrolimus Extended-Release (Envarsus XR) Use in Adolescent and Young Adult Solid Organ Transplant Recipients.
    Bae EK; Chandran MM; Everitt MD; Benz E; Bock M
    Clin Transplant; 2024 Aug; 38(8):e15417. PubMed ID: 39087462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to, and patient convenience of, prolonged-release tacrolimus in stable kidney and liver transplant recipients after conversion from immediate-release tacrolimus in routine clinical practice in Switzerland.
    Bonani M; Balaphas A; Bedino G; Bühler L; Dutkowski P; Fausch K; Gluderer S; Graf N; Hirt-Minkowski P; Müllhaupt B; Schönholzer C; Schulz MM; Venzin R; Wüthrich RP
    Swiss Med Wkly; 2021 Feb; 151():w20453. PubMed ID: 33638353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation.
    Beckebaum S; Iacob S; Sweid D; Sotiropoulos GC; Saner F; Kaiser G; Radtke A; Klein CG; Erim Y; de Geest S; Paul A; Gerken G; Cicinnati VR
    Transpl Int; 2011 Jul; 24(7):666-75. PubMed ID: 21466596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of converting adult kidney transplant recipients with high tacrolimus variability from twice daily immediate release tacrolimus to once daily LCP-Tacrolimus.
    Taber DJ; Bartlett F; Patel N; Sprague T; Patel S; Newman J; Andrade E; Rao N; Salas MAP; Casey M; Dubay D; Rohan V
    Clin Transplant; 2023 May; 37(5):e14941. PubMed ID: 36809653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Conversion to Once-Daily Tacrolimus from Twice-Daily Tacrolimus in Pediatric Liver Transplant Recipients.
    An S; Lee S; Rhu J; Kim JM; Choi GS; Joh JW
    J Pediatr Surg; 2023 Oct; 58(10):2054-2058. PubMed ID: 37277238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial.
    Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S
    Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan.
    Uemoto S; Abe R; Horike H; So M
    Transplant Proc; 2014 Apr; 46(3):749-53. PubMed ID: 24767340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Medication Adherence with the Use of Extended-Release Tacrolimus in Liver Transplant Recipients: A Pilot Randomized Controlled Trial.
    Verma M; Zaki R; Sadeh J; Knorr JP; Gallagher M; Parsikia A; Navarro V
    J Transplant; 2023; 2023():7915781. PubMed ID: 36642992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MeltDose Technology vs Once-Daily Prolonged Release Tacrolimus in De Novo Liver Transplant Recipients.
    Baccarani U; Velkoski J; Pravisani R; Adani GL; Lorenzin D; Cherchi V; Falzone B; Baraldo M; Risaliti A
    Transplant Proc; 2019 Nov; 51(9):2971-2973. PubMed ID: 31607620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients.
    Pape L; Heidotting N; Ahlenstiel T
    Int J Nephrol; 2011; 2011():126251. PubMed ID: 21647310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients.
    Dumortier J; Guillaud O; Boillot O
    Liver Transpl; 2013 May; 19(5):529-33. PubMed ID: 23483701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-center, open-label, randomized cross-over study to evaluate the pharmacokinetics and bioavailability of once-daily prolonged-release formulations of tacrolimus in de novo liver transplant recipients.
    Herden U; Sterneck M; Buchholz BM; Achilles EG; Ott A; Fischer L
    Immun Inflamm Dis; 2021 Dec; 9(4):1771-1780. PubMed ID: 34559956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of once-daily ER-Tac on trough concentration variability in a stable AYA renal transplant recipient cohort.
    Chandran MM; Blanchette E; Goebel J; Bock M
    Pediatr Transplant; 2021 Sep; 25(6):e14036. PubMed ID: 34003550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of the conversion to MeltDose
    Sánchez Fructuoso A; Ruiz JC; Franco A; Diekmann F; Redondo D; Calviño J; Serra N; Aladrén MJ; Cigarrán S; Manonelles A; Ramos A; Gómez G; González Posada JM; Andrés A; Beneyto I; Muñiz AL; Perelló M; Lauzurica R
    Clin Transplant; 2020 Jan; 34(1):e13767. PubMed ID: 31815310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the conversion to extended-release tacrolimus from immediate-release tacrolimus in liver transplant recipients.
    Choi D; Thaker S; West-Thielke P; Elmasri A; Chan C
    Eur J Gastroenterol Hepatol; 2021 Aug; 33(8):1124-1128. PubMed ID: 34213506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.